Q1 Earnings Estimate for VNDA Issued By HC Wainwright

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Research analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Vanda Pharmaceuticals in a research note issued on Monday, March 2nd. HC Wainwright analyst R. Selvaraju forecasts that the biopharmaceutical company will post earnings per share of ($0.28) for the quarter. HC Wainwright has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at ($0.07) EPS and Q4 2027 earnings at ($0.03) EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.18) by ($0.21). The business had revenue of $57.22 million for the quarter, compared to analysts’ expectations of $59.28 million. Vanda Pharmaceuticals had a negative net margin of 102.02% and a negative return on equity of 23.85%.

Several other analysts also recently weighed in on VNDA. Zacks Research downgraded Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 18th. Wall Street Zen downgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, December 17th. B. Riley Financial boosted their price objective on shares of Vanda Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, December 31st. Finally, Jefferies Financial Group upped their price objective on shares of Vanda Pharmaceuticals from $5.00 to $7.50 and gave the company a “hold” rating in a research note on Wednesday, December 31st. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Vanda Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $14.13.

Vanda Pharmaceuticals Trading Down 4.0%

Shares of VNDA stock opened at $7.84 on Wednesday. The stock has a market capitalization of $463.42 million, a PE ratio of -2.10 and a beta of 0.55. Vanda Pharmaceuticals has a 1-year low of $3.81 and a 1-year high of $9.60. The business has a 50-day moving average of $7.53 and a 200 day moving average of $5.96. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.39 and a quick ratio of 2.38.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Torren Management LLC purchased a new position in shares of Vanda Pharmaceuticals during the fourth quarter valued at about $25,000. Bailard Inc. boosted its position in Vanda Pharmaceuticals by 16.2% during the 2nd quarter. Bailard Inc. now owns 26,100 shares of the biopharmaceutical company’s stock valued at $123,000 after acquiring an additional 3,631 shares in the last quarter. Panagora Asset Management Inc. grew its holdings in shares of Vanda Pharmaceuticals by 3.4% during the 4th quarter. Panagora Asset Management Inc. now owns 118,987 shares of the biopharmaceutical company’s stock worth $1,049,000 after acquiring an additional 3,928 shares during the period. Jane Street Group LLC grew its holdings in shares of Vanda Pharmaceuticals by 6.1% during the 2nd quarter. Jane Street Group LLC now owns 79,107 shares of the biopharmaceutical company’s stock worth $373,000 after acquiring an additional 4,533 shares during the period. Finally, Savant Capital LLC raised its position in shares of Vanda Pharmaceuticals by 30.3% in the 3rd quarter. Savant Capital LLC now owns 22,493 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 5,229 shares in the last quarter. 88.14% of the stock is owned by hedge funds and other institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.